Publications — Radcliffe Department of Medicine

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events.

Wightman H. et al, (2025), PLoS Med, 22

Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023).

Golubic R. et al, (2025), Diabetes Obes Metab

Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242.

Maddaloni E. et al, (2025), Diabetes Care, 48, e61 - e62

Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: Insights from an EXSCEL post-hoc analysis.

Maddaloni E. et al, (2025), Diabetes Res Clin Pract

Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysis.

Juraschek SP. et al, (2025), BMJ, 388

Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities

Loesch DP. et al, (2025), Nature Communications, 16

Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes.

Sammons E. et al, (2025), BMJ Open, 15

A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.

Dennis JM. et al, (2025), Lancet

Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.

Hanlon P. et al, (2025), JAMA

Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.

Maddaloni E. et al, (2025), Diabetes Care, 48, 235 - 242

The Science of Diabetes and a Life of Trials: The 2024 Banting Medal for Scientific Achievement Award Lecture.

Holman RR., (2025), Diabetes, 74, 164 - 174

The legacy effect of hyperglycaemia in type 2 diabetes - Authors' reply.

Adler AI. et al, (2025), Lancet, 405

An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders

De Giorgi R. et al, (2025), Nature Mental Health

Cardiovascular Risk Prediction Scores in Type 1 Diabetes: A Systematic Review and Meta-Analysis

Erqou S. et al, (2025), JACC: Advances, 4

Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction.

Marx N. et al, (2024), Eur Heart J, 45, 5117 - 5126

Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

Golubic R. et al, (2024), Diabet Med

Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).

Lin B. et al, (2024), Lancet Diabetes Endocrinol

Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.

Neves JS. et al, (2024), Eur J Heart Fail

The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.

Klonoff DC. et al, (2024), J Diabetes Sci Technol

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial.

Koychev I. et al, (2024), Alzheimers Res Ther, 16

Load More

Include forthcoming?